126 related articles for article (PubMed ID: 16520271)
1. Overexpression of alpha-defensin is associated with bladder cancer invasiveness.
Holterman DA; Diaz JI; Blackmore PF; Davis JW; Schellhammer PF; Corica A; Semmes OJ; Vlahou A
Urol Oncol; 2006; 24(2):97-108. PubMed ID: 16520271
[TBL] [Abstract][Full Text] [Related]
2. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
3. Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer.
Watanabe R; Ohyama C; Aoki H; Takahashi T; Satoh M; Saito S; Hoshi S; Ishii A; Saito M; Arai Y
Cancer Res; 2002 Jul; 62(13):3850-4. PubMed ID: 12097299
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
[TBL] [Abstract][Full Text] [Related]
5. Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.
Swellam M; El-Aal AA; AbuGabel KM
Clin Biochem; 2004 Dec; 37(12):1098-104. PubMed ID: 15589816
[TBL] [Abstract][Full Text] [Related]
6. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
7. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
8. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells.
Satoh M; Ito A; Nojiri H; Handa K; Numahata K; Ohyama C; Saito S; Hoshi S; Hakomori SI
Int J Oncol; 2001 Oct; 19(4):723-31. PubMed ID: 11562747
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-143 as a tumor suppressor for bladder cancer.
Lin T; Dong W; Huang J; Pan Q; Fan X; Zhang C; Huang L
J Urol; 2009 Mar; 181(3):1372-80. PubMed ID: 19157460
[TBL] [Abstract][Full Text] [Related]
10. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
13. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis.
Tolson JP; Flad T; Gnau V; Dihazi H; Hennenlotter J; Beck A; Mueller GA; Kuczyk M; Mueller CA
Proteomics; 2006 Jan; 6(2):697-708. PubMed ID: 16252305
[TBL] [Abstract][Full Text] [Related]
14. Expression of the VLA beta 1 integrin family in bladder cancer.
Liebert M; Washington R; Stein J; Wedemeyer G; Grossman HB
Am J Pathol; 1994 May; 144(5):1016-22. PubMed ID: 8178925
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer.
Atlasi Y; Mowla SJ; Ziaee SA
Cancer Detect Prev; 2009; 32(4):308-13. PubMed ID: 19186007
[TBL] [Abstract][Full Text] [Related]
16. The role of actinin-4 in bladder cancer invasion.
Koizumi T; Nakatsuji H; Fukawa T; Avirmed S; Fukumori T; Takahashi M; Kanayama H
Urology; 2010 Feb; 75(2):357-64. PubMed ID: 19969329
[TBL] [Abstract][Full Text] [Related]
17. p63 gene expression study and early bladder carcinogenesis.
Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
[TBL] [Abstract][Full Text] [Related]
18. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
19. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
